Here we aimed to evaluate in females: (1) effects of SPS on stress-related behavior; (2) a dose response effect and therapeutic dose of intranasal NPY for SPS-elicited behaviors; and (3) the role of NPY cleavage in the high dose requirement of intranasal NPY for treatment of stress-related disorders using the DPP4 inhibitor omarigliptin. The gene discussed is NPY; the disease is stress-related disorder.